Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea
Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa
Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
Nxera Announces Conclusion of Buyback for Existing Convertible Bonds
Nxera Pharma to Regain Full Rights to GPR52 Agonist Program for Schizophrenia
Nxera Announces Results of Buyback and Consent Solicitation for Existing Convertible Bonds
Notice Regarding Receipt of Dividends from Consolidated Subsidiary
Notice Regarding Change in Major Shareholder and Largest Shareholder
[Summary] Nxera Announces Buyback and Consent Solicitation for Existing Convertible Bonds
Nxera Introduces Employee Stock Ownership Plan (J-ESOP) for Employees Residing in Japan
Nxera Announces Focused Restructuring to Enhance Path to Profitability
Consolidated Financial Results for the Nine months Ended September 30, 2025 (IFRS)
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025
Consolidated Financial Results for the Six months Ended June 30, 2025 (IFRS)
Consolidated Financial Results for the Six months Ended June 30, 2025 (IFRS)
Consolidated Financial Results for the Six months Ended June 30, 2025 (IFRS)